Results 181 to 190 of about 3,677,242 (302)

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Retraction: Molecular Pathology in Modern Medicine: A Review of Genomic, Proteomic, and Epigenetic Insights Into Disease Mechanisms. [PDF]

Cureus
Jayant S, Doley N, Swapna N, Prasad H, Sambhav K, Das B.   +5 more
europepmc   +1 more source

PAKISTANI MEDICINAL PLANTS: MIRACLE IN MEDICAL SCIENCE

The Bulletin of Contemporary Clinical Medicine, 2019
AKBAR KHAN NIAZI, MURAD MASTOI SHAH, FATIMA EJAZ, ABDUL GHAFFAR   +3 more
openaire   +1 more source

University of Arkansas for Medical Sciences College of Medicine

Academic Medicine, 2020
James, Graham, Sara, Tariq, Karina, Clemmons, Richard, Wheeler   +3 more
openaire   +3 more sources

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Correction: Toward a clearer vision: epidemiology and symptom-based clinical patterns of dry eye disease in the Saudi population. [PDF]

Front Med (Lausanne)
AlEissa MM, Mousa A, Alosimi HA, Alosimi RA, Alhawsawi AA, Alkharji R, AlQahtani AS, Alotibi RS, Alquwayfili SI, Ahmad S, Edward DP.   +10 more
europepmc   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Correction: Periplogenin attenuates LPS-mediated inflammatory osteolysis through the suppression of osteoclastogenesis via reducing the NF-κB and MAPK signaling pathways. [PDF]

Cell Death Discov
Gan K, Lian H, Yang T, Huang J, Chen J, Su Y, Zhao J, Xu J, Liu Q.   +8 more
europepmc   +1 more source

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

Molecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge, Morten Tulstrup, Gabriele Todisco, Pedro Moura, Christophe Côme, Jakob Werner Hansen, Jakob Schmidt Jespersen, Balthasar Schlotmann, Maria Creignou, Mette Dahl, Claudia Schöllkopf, Klas Raaschou‐Jensen, Krister Wennerberg, Bo Porse, Joachim Weischenfeldt, Eva Hellström‐Lindberg, Lasse Sommer Kristensen, Kirsten Grønbæk   +17 more
wiley   +1 more source

Prevention of oral mucositis in patients undergoing cancer chemotherapy using betamethasone mouthwash: A multicenter randomized controlled trial protocol. [PDF]

PLoS One
Soutome S, Hamada T, Nishi H, Iwata E, Nakahara H, Yamamoto T, Matsumura T, Nishikawa M, Tomihara K, Ueki K, Noda M, Shimanishi M, Funahara M, Kawahara M, Yamamura Y, Matsuda S, Yoshida K, Kanazawa S, Otsuji M, Natsume N, Umeda M, Research Committee of the Japanese Society of Oral Care.   +21 more
europepmc   +1 more source